1. H.I.G. BioVentures
July 29, 2011

2. H.I.G. Capital – Corporate Overview
H.I.G. is one of the leading private equity firms in the small-cap segment of the market
Founded in 1993; over $9 Billion under management
More than 200 investment professionals
Offices:
North America: Miami, Atlanta, Boston, San Francisco, New York, Maryland
Europe: London, Paris, Hamburg
H.I.G. Funds:
Venture/Growth Investments: H.I.G. BioVentures; H.I.G. Growth Partners
Buyout Investments: U.S. LBO, Europe LBO
Distressed Investments: Bayside Capital (debt)
Public Equities: Brightpoint Capital
“Institutionalized” management structure/processes with strong financial staff/controls,
legal/compliance, IT support, and risk management procedures in place
Differentiated, value-added strategy has resulted in superior track record 2

3. H.I.G. BioVentures – Background
Established dedicated life science focus in 2004 :
Approximately $350 Million in capital under management
$150 Million committed to existing portfolio companies
Currently investing out of H.I.G. BioVentures II
Experienced team focused exclusively on life science investing
Sectors: biopharmaceuticals, medical devices, diagnostics
H.I.G. BioVentures is the lead or co-lead investor in all investments
Active board representation in all companies 7

4. H.I.G. BioVentures – Team
Four senior investment professionals with collectively more than 30 years of venture capital investing experience
The H.I.G. BioVentures team has complementary backgrounds covering
Research and intellectual property
Product and process development
Business development
Operations
Finance
Sales and marketing
The H.I.G. BioVentures team also has a deep network of advisors, co-investors, corporate leaders, and technical consultants to leverage during due diligence and on behalf of portfolio companies 8

5. H.I.G. BioVentures – Industry Leadership
The H.I.G. BioVentures team is active with numerous academic and non-profit organizations
Boards of regional venture capital organizations:
Mid-Atlantic Venture Association (MAVA), FL Bio, GA Bio
Board and committee participation at national and regional conferences:
Bio-Investor Forum, Mid-Atlantic Bio, Southeast Bio Investor Forum, FL Venture Forum, Midwest Healthcare Investor Network
Board/advisory member for universities and entrepreneurial organizations :
Johns Hopkins Alliance, Maryland Technology Enterprise Institute, North Texas Enterprise Corporation, Texas Bioscience Council, Coulter Foundation (Emory, Ga. Tech), Sid Martin Biotechnology Incubator , Univ. Miami, Univ. Florida, Univ. Delaware Research Foundation, Virginia CIT Gap Fund Investment Board (affiliated with all Virginia Universities), Enterprise Florida
Not-for-profit boards :
Adventist Healthcare
Speaker/panelist :
Multiple national and regional conferences including BIO 2011 9

6. H.I.G. BioVentures – Aaron Davidson
Executive management at Eli Lilly and Company
Business development
Sales and marketing
Finance
General management
Venture capital experience at Ventures West
Leading Canadian healthcare investor
Operating history at Eli Lilly and Company and venture-backed SYN-X Pharma
Broad network in the pharmaceutical and biotechnology industry as well within the venture capital community.
M.B.A., Harvard Business School
B.Comm., McGill University
(305) 10

7. H.I.G. BioVentures – Bruce Robertson
Operating experience in both business development
and R&D
IGEN (acquired by Roche)
W.R. Grace
Venture capital experience at Toucan Capital and
GIV Venture Partners
Extensive relationships in the Mid-Atlantic’s financial, entrepreneurial and scientific/academic community
Well-connected within broad venture capital community
M.B.A., Harvard Business School
Ph.D., University of Delaware (Biomedical Engineering)
B.S.E., University of Pennsylvania
(305) 11

8. H.I.G. BioVentures – Michael Wasserman
Operating experience in entrepreneurial/venture-
backed biotechnology
Founder and VP, Business Development at CELLutions Biosystems (acq. by Cedarlane Labs)
Background in early-stage technology transfer and development as
a Principal with Innovations Foundation
Clinical drug development and regulatory expertise based on tenure
at Advanced Therapeutics
Extensive network and deal flow resources in multiple geographies – Southeast, Midwest, Texas, Ohio, etc.
Ph.D., University of Toronto (Pharmacology)
B.S., McGill University
(305) 12

9. H.I.G. BioVentures – Michael Gutch
Venture Capital experience at Lilly Ventures,
Eli Lilly and Company
Member of the Corporate Finance & Investment
Banking group at Eli Lilly and Company
Post-doctoral research experience at Cold Spring Harbor Labs and UCSF
Strong associations in the pharmaceutical and entrepreneurial communities and networked throughout the Midwest and Northwest
M.B.A., Indiana University
Ph.D., State University of New York (Molecular & Cellular Pathology)
B.S., Alfred University
(305) 13

10. H.I.G. BioVentures – Investment Strategy
Areas of Unmet
Medical Need
Efficient Clinical
Development
Validation &
Differentiation
Broad Source of
Deal Flow
Large, attractive markets
Significant unmet medical needs
Chronic or acute care high
value per patient disease
indications
Clear and meaningful clinical end-points
Short clinical development timelines to demonstrate proof-of-concept in appropriate patient groups
Scientific and clinical validation well established
Differentiation from current standard of care
Regulatory precedent established
Extensive networks outside of CA and MA resulting in proprietary deal flow
Approximately 80% of investments in “secondary geographies” 14

11. H.I.G. BioVentures – Partnering with Industry
H.I.G. BioVentures values its long-term relationships with the pharma and medical device industries
H.I.G. BioVentures has:
Co-invested with corporate venture capital groups such as MedImmune Ventures, SROne, Novo A/S
Strong relationships with most pharmaceutical and med-tech corporate venture capital and business development groups
Ongoing discussions with CVC and BD groups on existing portfolio companies and new deal opportunities
H.I.G. BioVentures portfolio companies have recently completed transactions with: 17

12. H.I.G. BioVentures – Summary
Dedicated to investing in high potential life sciences companies
Team of experienced investment professionals with deep domain knowledge
Proprietary deal flow developed through a broad relationship network
Ability to leverage the more than 200 investment professionals across the H.I.G. Capital platform
Building business relationships with pharmaceutical, biotechnology, and medical device companies 18

13. Questions?